Blog

European HealthTech this week is dominated by EU‑level regulatory moves around MDR/IVDR and AI, plus a clear pivot of digital health from “experiments” to scaled implementation and validation funding.EU regulatory and policy moves The Commission has advanced a 2026 Health Package revising MDR/IVDR to ease bottlenecks: more predictable conformity assessment, codified “Helsinki procedure” for borderline products, and risk‑based (rather than fixed 5‑year) certificate validity.​ Cybersecurity is being hard‑wired into MDR/IVDR, with obligations to report actively exploited vulnerabilities and severe cyber incidents in medical devices within 30 days, aligning with broader EU cyber rules.​ Digitalisation provisions will allow EU declarations of conformity and some IFUs in digital‑only form and require fully electronic submissions into EUDAMED; four core EUDAMED modules went live in late 2025, triggering a transition to mandatory use from May 2026.​ EU machinery for joint clinical assessments under the HTA Regulation is now live, with more MedTech expected to enter the pipeline during 2026, raising the bar for clinical evidence in market access dossiers.​ AI Act, SaMD and medical AI Work is ongoing to integrate AI Act “high‑risk” obligations with MDR/IVDR so high‑risk medical AI can go through a single sectoral conformity route, avoiding duplicated certification; core AI Act obligations are expected to apply from around August 2026.​ Recent analysis and events (e.g. EUCROF’s focus on SaMD and AI) highlight that MDR and the upcoming AI Act are reshaping compliance and commercialization strategies for software as a medical device, including real‑world examples such as Healthentia. Industry and policy fora this week (e.g. “Masters of Digital 2026”, MWC/4YFN “AI in Healthcare: Hype or Hope?”) are centering on AI governance in care delivery and diagnostics rather than just technical capabilities. Market environment, exits and consolidation EU data show sustained pressure on MedTech innovation portfolios, with reduced pipelines, cancelled launches and some manufacturers exiting EU markets due to MDR/IVDR cost and complexity, which is pushing resource re‑allocation and go/no‑go decisions.​ Analysts expect consolidation driven by regulatory complexity, with larger hardware incumbents and big tech acquiring software/data innovators to secure “compliance moats” and data sovereignty under the evolving EU regulatory stack.​ At CES 2026, European AI‑driven MedTech companies were already positioning offerings for US reimbursement and institutional contracting, underlining continued internationalisation despite home‑market frictions.​ Funding, grants and validation capital Global Health EDCTP3 has opened 2026 calls with up to €147m across six topics (TB, LRTIs, HIV/co‑morbidities, climate‑linked infectious disease), explicitly supporting digital/clinical innovation and data‑/AI‑heavy platforms.​ Within the Horizon Europe 2026–27 work programme, a substantial part of a €14bn R&amp;I envelope is earmarked for health and digital technologies, reinforcing medium‑term grant support for AI, data and platform‑driven health innovation. EIT Health just launched its 2026 Innovation Validation Call, funding up to 50% of project budgets (max €850k) to accelerate clinical validation, regulatory approval and market launch for late‑stage digital, data and AI‑driven healthcare innovations.​ Ecosystem, infrastructure and events Analysis this week frames European digital health as entering a “proof through exits” phase, with investor focus shifting from round size to scalability, regulatory readiness and clear paths to liquidity. health.tech 2026 in Basel and European Digital HealthTech‑linked events are emphasizing implementation: deploying AI in workflows, prevention systems, and aligning with EHDS, SaMD/AI regulation, and procurement rules. There is renewed emphasis on EHR maturity and interoperability as prerequisites for scaling teleconsultations and virtual care; WHO experts underline that robust EHR infrastructure is essential for digital health service expansion.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;European MedTech this week is centred on the EU “Health Package” (MDR/IVDR reset plus biotech/clinical trials tweaks), upcoming Commission discussions on devices, and a continued narrative of consolidation and “compliance‑driven” strategy.MDR/IVDR “regulatory reset” The Commission has proposed targeted amendments to MDR and IVDR to simplify requirements, reduce administrative burden and improve notified body predictability, responding to evidence of reduced pipelines, cancelled launches and exits from the EU market. Key elements include more proportionate, risk‑based rules (e.g. updated classification such as a refined Rule 11 for software), removal of fixed certificate validity in favour of validity limited only when risk justifies it, and priority review paths for breakthrough or orphan devices. Manufacturers would benefit from clearer rules on post‑certification changes, structured dialogue with notified bodies, digital Declarations of Conformity and eIFUs, and reduced PSUR frequency, with fee reductions and support measures for micro and small enterprises.​ Timelines and stakeholder input The legislative proposal is at EU co‑decision stage; it must be adopted by Parliament and Council and may be amended during the process.​ An eight‑week feedback window is open into mid‑March 2026 for stakeholders to comment on the MDR/IVDR changes, with submissions shared with EU legislators.​ In parallel, AI Act implementation work continues, with plans to allow high‑risk medical AI to use a single MDR/IVDR‑anchored conformity route rather than duplicative AI Act certification when obligations overlap.​ Innovation, safety and procurement agenda On 16 March 2026, the Commission will host a high‑level conference in Brussels on “Medical Devices: Innovation and Patient Safety,” covering predictability of conformity assessment, the role of expert panels in clinical evidence, and guidance for breakthrough technologies. New EU proposals are also set to reshape procurement for MedTech and diagnostics, which could materially affect pricing, value‑based criteria and access for both incumbents and innovators.​ The EU HTA Regulation machinery is now operational, and more MedTech is expected to enter joint clinical assessments in 2026, raising the evidentiary bar for pan‑EU market access.​ Market structure, M&amp;A and capital Analysts highlight ongoing pressure on MedTech innovation portfolios from MDR/IVDR‑driven costs and complexity, prompting portfolio pruning and re‑prioritisation of launches. A distinct “compliance‑driven M&amp;A” theme is emerging, with strategics acquiring targets partly to secure regulatory “compliance moats” and de‑risk EU market access, while PE pursues buy‑and‑build strategies in fragmented segments. Transatlantic capital flows remain strong, with US corporate and growth funds active in European robotics and AI‑driven MedTech, helping to bridge the historical Series B+ gap and allowing companies to scale further before exit. Internationalisation and AI‑driven MedTech European AI‑driven MedTech players are increasingly designing offerings around US reimbursement and institutional contracting, as showcased at CES 2026, reflecting a push to scale outside Europe while regulatory reforms work through at home. Upcoming European events (e.g. Athens Digital Health Week, European Digital HealthTech Conference) are being used as coordination points on EHDS implementation and SaMD/AI adoption in routine care, which directly impacts device‑plus‑software business models.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

This Week in European MedTech and HealthTech: 13th March 2026

UCL Global Business School for HealthThe UCL Global Business School for Health is the world's first business school dedicated to health. We unravel health challenges from a business perspective.Established in 2021, the UCL Global Business School for Health (GBSH) was created in response to an undeniable global truth: health systems must evolve. The pandemic highlighted the profound impact of health on society, exposing critical system flaws and the need for better management, innovation, and leadership.UCL GBSH’s one-of-a-kind offering of undergraduate, postgraduate and Executive Education courses address these issues head-on, providing management and business skills to students from across the world. From focusing on public health engagement to harnessing the power of technology and digitisation, we are preparing our students to lead health transformation globally.Health Executives in Residence Being leaders in their respective fields and industries, our Health Executives in Residence are not only here to help you reimagine healthcare for the future but are also here to ensure you graduate from the Global Business School for Health with experiences that mirror the real work of health. We believe that the interactions you have with our Health Executives in Residence will challenge and shape your aspirations and career paths.&nbsp;UCL Health Executives in Residence include a wide range of industry leaders and innovators including:Michael Allen - Partner and Head of Health &amp; Human Services, KPMGDr Dominique Allwood - Chief Executive, Imperial College Health PartnersMinal Bakhai - National Director of Primary Care and Community Transformation and Improvement, NHSDr Jonathan Broomberg - Group Deputy CEO, VitalityChris Gibbons - Director of Digital Health &amp; Technology Transformation, KPMGDr Joanne Hackett - Vice President Health System Services, IQVIAAndreas Haimböck-Tichy - Managing Director, Healthcare Accenture UKJohanna Moss - Director of Strategy, University College London Hospitals (UCLH)Ben Osborn - President, International Commercial Office, PfizerLloyd Price - Founder and Partner, Nelson AdvisorsSara Siegel - Global Health Sector Leader and Lead Partner for Healthcare, DeloitteAdrian Stevensen - CEO, Independent CareMing Tang - Chief Data and Analytics Officer, NHS EnglandDr Susan Thomas - Director, Google for Health, EMEASource: <a href="https://www.ucl.ac.uk/population-health-sciences/global-business-school-health/people" data-mce-href="https://www.ucl.ac.uk/population-health-sciences/global-business-school-health/people">https://www.ucl.ac.uk/population-health-sciences/global-business-school-health/people</a>

Nelson Advisors invited to UCL GBSH Health Executives in Residence Programme

The strategic landscape of digital health in the National Health Service (NHS) is currently undergoing a foundational shift, characterised by a transition from a decentralised, market-led model of patient engagement to a highly centralised, state-curated "digital front door" model.&nbsp; &nbsp;&nbsp; This evolution has been accelerated by the recent announcement that NHS England will cease central funding for the Wayfinder program by March 2026, a move that coincides with a broader cost-containment drive aimed at "dismantling" the established market for third-party patient engagement portals (PEPs).&nbsp; &nbsp;&nbsp; While these developments have raised concerns regarding the sustainability of patient engagement, a rigorous analysis of the "10 Year Health Plan" and the accompanying productivity strategies reveals that engagement is not being abandoned but is instead being redefined as a core national utility delivered through the NHS App.&nbsp; &nbsp;&nbsp; The future patient experience is being architected around a Single Patient Record (SPR) and a centralised Patient Care Aggregator (PCA), shifting the role of third-party suppliers from patient-facing platforms to back-end "engines" that facilitate standardised national workflows.The Wayfinder Program: Success, Scale and the Rationale for Centralisation &nbsp;&nbsp; The Wayfinder program, formally designated as the Secondary Care Integration program, was established to address the fragmentation inherent in the NHS’s elective care pathways by providing patients with a unified view of their hospital referrals and appointments. By April 2025, the program had achieved substantial operational success, with 114 NHS trusts integrated into the service and over 130 million patient interactions recorded. The technical mechanism for this success was the Patient Care Aggregator (PCA), a centralised infrastructure that retrieves booking data from disparate secondary care systems and surfaces them within the NHS App. Despite this momentum, the decision to end central funding for the Wayfinder national support program in March 2026 reflects a pivot in policy toward "direct integration". The government argues that the current model, which often requires trusts to procure third-party portals as intermediaries between their local Electronic Patient Records (EPRs) and the NHS App, is duplicative and unnecessarily expensive. By bypassing these intermediaries and wiring hospital systems directly into the national app, NHS England expects to achieve a standardised, "single pane of glass" experience for millions of citizens while simultaneously realising an estimated £11 Million in annual recurring savings.Read the report here - <a href="https://www.healthcare.digital/single-post/the-strategic-evolution-of-patient-engagement-in-the-nhs-the-post-wayfinder-era-and-consolidation-o">https://www.healthcare.digital/single-post/the-strategic-evolution-of-patient-engagement-in-the-nhs-the-post-wayfinder-era-and-consolidation-o</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Dismantling the Market: The End of Standalone Patient Portals across the NHS?

Strategic Analysis of the HealthTech and MedTech Ecosystem on the FTSE AIM: Navigating Fiscal Reform, Regulatory Evolution, and the Digital Transformation of Healthcare in 2026 The Alternative Investment Market (AIM) of the London Stock Exchange has historically served as a critical incubator for high-growth healthcare technology and medical device companies, providing a unique environment where innovative small-to-mid-cap entities can access public capital while benefiting from a more flexible regulatory regime than the Main Market. As of March 2026, the sector is characterised by a profound transition.&nbsp;Strategic Recommendations for 2026 The healthtech and medtech sectors on the FTSE AIM in 2026 represent a classic "risk-on, risk-off" scenario. The structural transition of the NHS provides a "generational tailwind" for digital health, yet the rebalancing of the UK’s fiscal regime creates a near-term valuation challenge for the AIM platform itself. For Investors: Focus on "Health Tech 2.0" &nbsp; Investors should prioritize companies that exhibit the characteristics of the "Health Tech 2.0" wave: durable revenue, software-like margins at scale, and technologies that solve specific productivity problems in the healthcare stack. While the 20% effective IHT charge on AIM shares is a factor, it should be weighed against the tax-free gains available within an ISA and the potential for "outsized returns" in companies targeted for global M&amp;A. &nbsp; For Companies: Embrace International Reliance and Sandboxes &nbsp; AIM-listed firms must proactively engage with the MHRA’s new frameworks. Utilizing the "international reliance" model can significantly reduce time-to-market and conserve capital. Furthermore, participation in initiatives like the AI Airlock or Sovereign AI Growth Zones provides access to infrastructure and regulatory insights that are difficult to replicate on other markets. Final Market Outlook &nbsp; The year 2026 is likely to be a "re-rating" period for the UK stock market. While the FTSE 100 has reached record highs, the small-and-mid-cap indices, including AIM, are valued at their "cheapest in 23 years" on several metrics. As global investors look to diversify away from US mega-cap concentration, the high-quality healthcare businesses on AIM—characterized by world-class research and a "solid history" of innovation—represent a compelling value opportunity for those with a multi-year horizon.&nbsp; &nbsp; The "trust gap" in valuations is real, but as these companies continue to demonstrate sustainable high growth quarter after quarter, the gap is expected to narrow, rewarding patient and discerning capital.The intersection of the United Kingdom government’s 10-Year Health Plan, significant reforms to inheritance tax treatments, and a maturing artificial intelligence landscape has created a market environment defined by both systemic headwinds and transformative tailwinds. This report provides an exhaustive analysis of the healthtech and medtech companies listed on the FTSE AIM, evaluating the core drivers of performance, the risks inherent in the current fiscal landscape, and the strategic alternatives available to firms and investors alike.Read the full report here <a href="https://www.healthcare.digital/single-post/strategic-analysis-of-the-healthtech-and-medtech-ecosystem-on-the-ftse-aim">https://www.healthcare.digital/single-post/strategic-analysis-of-the-healthtech-and-medtech-ecosystem-on-the-ftse-aim</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk

Analysis of the HealthTech and MedTech Ecosystem on the FTSE AIM

Today the biggest issues cluster around three themes: capital is more selective and milestone‑driven, regulation is getting heavier and more complex (MDR/IVDR + AI Act + data) and commercial proof is now non‑negotiable for both founders and investors.1. Funding climate and deal dynamics Digital health and broader healthtech have come off the 2021 peak; deal volumes are down sharply versus the boom years, even where absolute funding has rebounded or remained resilient, so capital is there but harder to access. Investors are much more selective, concentrating on later‑stage or de‑risked assets (e.g. growth rounds, scaling proven solutions) and pushing earlier companies to show clearer paths to inflection points within 12–18 months. MedTech in particular faces a “double squeeze”: inherently long, capital‑intensive development cycles versus investors demanding faster proof points, making rounds slower, more dilutive, and often tranched or milestone‑based.​ For many companies, strategic/industrial partnerships (distribution, licensing, carve‑outs, early M&amp;A) have become as important as classic VC, because strategics can bring market access, regulatory infrastructure, and manufacturing. 2. Regulatory burden and uncertainty MDR and IVDR continue to impose heavy documentation, clinical evidence, and post‑market surveillance requirements that weigh especially on SMEs and lengthen time‑to‑market and time‑to‑funding.​ The EU AI Act now classifies most medical AI as “high‑risk,” adding obligations on logging, robustness, human oversight and governance on top of MDR/IVDR, with industry bodies warning about overlapping and potentially duplicative requirements. Uncertainty around how AI Act, MDR/IVDR and national implementations will be harmonised creates planning risk for product roadmaps; investors factor this into risk‑adjusted valuations and sometimes push companies to other geographies or to purely “non‑medical” use cases. Founders must invest earlier in quality systems, regulatory strategy, and notified‑body interactions, which increases burn pre‑revenue and makes early “experimentation” harder. 3. Evidence, reimbursement and commercial traction Both buyers and investors now expect robust clinical and health‑economic evidence, not just promising tech; assets that cannot demonstrate measurable clinical impact struggle to raise or win pilots. Hospital and payer procurement remains slow, fragmented, and highly cost‑pressured, so even validated solutions face long sales cycles and tough price negotiations, delaying revenue ramp and increasing working‑capital needs. Reimbursement for digital health, AI and novel MedTech is still patchy across Europe, with varying national schemes and coding, making cross‑border scaling complex and reducing investors’ confidence in pan‑European roll‑outs. As a result, profitability, recurring revenue and proved unit economics have become central screening criteria for investors and acquirers, rather than “nice‑to‑have” upside. 4. Market fragmentation and scaling challenges Europe remains structurally fragmented by language, regulation, reimbursement, and clinical practice; even though funding has rebounded and healthtech is one of the most funded sectors, this fragmentation makes scaling sales and operations expensive. There is growing geographic specialisation of VC funds and ecosystems, which helps with local nuance but can hinder pan‑European syndication and create “regional silos” for founders trying to scale. The MedTech industry is dominated by tens of thousands of SMEs, making the ecosystem sensitive to any tightening in funding, regulatory bottlenecks, or procurement delays.​ 5. Strategic alignment between founders and investors Investors increasingly demand clear alignment on regulatory, clinical and commercial milestones, and penalise “vision without execution plan,” especially in AI and data‑driven models. There is tension between founders pursuing broad platform or multi‑indication stories and investors preferring focused, vertical solutions with clear beachheads and exit pathways. Exit markets (IPOs, large M&amp;A) remain cautious due to macro pressures, so investors push more for structured rounds, strong governance, and early optionality around strategic exits rather than late, valuation‑maximising IPOs.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

What are the biggest issues in European HealthTech and MedTech for founders and investors today?

This Week in European HealthTech: 6th March &nbsp;2026EU policy and regulation The European Commission has tabled a new “Health Package” that includes the first phase of an EU Biotech Act plus targeted amendments to the Clinical Trials Regulation to speed set‑up and boost Europe’s competitiveness in life sciences.​ As part of the same package, proposed revisions to MDR/IVDR would remove the fixed five‑year certificate validity cap and move to risk‑based surveillance, aimed at reducing administrative burden and improving predictability for device and IVD manufacturers.​ The revision also hard‑wires cybersecurity into MDR/IVDR, obliging manufacturers to report actively exploited vulnerabilities and severe cyber incidents affecting medical devices within 30 days, aligned with wider EU cyber frameworks. EU‑level work continues on integrating AI Act obligations with MDR/IVDR so that high‑risk medical AI can go through a single sectoral conformity route rather than duplicated certification, with most AI Act core obligations due to apply by August 2026.​ In parallel, the EU HTA Regulation machinery is now live, with initial joint clinical assessments already underway and more technologies, including MedTech, expected to enter the pipeline in 2026, setting the tone for future market access dossiers.​ Digital health and AI ecosystem Policy discussions this week are heavily focused on whether EU health policy can keep pace with the AI wave in care delivery and diagnostics, with AI governance in health a central topic at industry fora such as “Masters of Digital 2026”.​ Recent analysis highlights that countries with well‑developed electronic health records and interoperable platforms are better positioned to scale teleconsultations and other virtual care models, keeping infrastructure and data interoperability high on national agendas.​ European‑level events like Athens Digital Health Week 2026 and the upcoming European Digital HealthTech Conference are being used to coordinate around EHDS implementation, regulatory issues for SaMD/AI, and adoption of digital medical devices in routine care. Funding, grants and public money Global Health EDCTP3 has opened its 2026 calls with up to €147m available across six topics, funding R&amp;I on TB, lower respiratory tract infections, HIV (including co‑morbidities), and climate‑linked infectious disease, all of which have clear digital/clinical innovation angles.​ Within the wider Horizon Europe 2026–2027 work programme, a significant slice of a €14bn R&amp;I envelope is earmarked for health and digital technologies, reinforcing medium‑term grant support for AI‑, data‑ and platform‑driven health innovation.​ Europe’s digital health investment landscape is being framed as entering a “proof through exits” phase in 2026, after leading global growth in 2025, with scrutiny shifting from round size to scalability, regulatory readiness and path to liquidity.​ Market and infrastructure signals Analysis of European digital health maturity underlines large variance in teleconsultation share and EHR access across member states, with WHO experts reiterating that robust EHR infrastructure is a prerequisite for scaling digital health services.​ EU‑level efforts such as All Digital Weeks (9–25 March 2026) are being used to push digital skills and literacy, which are increasingly seen as enablers for adoption of patient‑facing and clinician‑facing digital health tools.​ Continued clarification of MDR/IVDR, EUDAMED roll‑out, and AI Act timelines is expected to shift MedTech/HealthTech focus from “regulatory uncertainty risk” towards execution on scale‑up and cross‑border deployment over the next 18–24 months. What this likely means for deals Near term, the Health Package proposals around MDR/IVDR and biotech/clinical trials should ease regulatory risk in diligence, but also harden expectations around cybersecurity and AI governance in targets’ product roadmaps. The EDCTP3 and Horizon Europe envelopes create non‑dilutive capital for infectious‑disease‑linked platforms and data/AI‑heavy solutions, which may support pipeline building for future M&amp;A rather than immediate large rounds. With EU HTA structures and AI Act timelines clearer, assets positioned as “AI‑enabled devices/diagnostics” will be judged more on HTA‑ready evidence packages and integrated quality systems than on novelty of algorithms alone.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;This Week in European MedTech: 6th March &nbsp;2026MDR/IVDR and core EU regulatory movesThe Commission has advanced targeted revisions to MDR and IVDR as part of the 2026 Health Package, aiming to streamline processes and reduce burdens while maintaining safety; this includes adjustments to conformity assessment predictability and notified body oversight. The amending regulation also further codifies the “Helsinki procedure” for consistent product qualification and device classification across member states, with expanded use of expert panels for borderline products and complex classifications.​ Digitalisation provisions would allow EU declarations of conformity and certain IFUs to be provided in digital form only, and require economic operators to submit MDR/IVDR information electronically with digital contact details registered in EUDAMED.​ EUDAMED’s next phase is on track: four core modules became fully functional in late 2025, triggering a six‑month transition; from 28 May 2026, manufacturers and other actors must comply with enhanced transparency and registration obligations under MDR/IVDR. The Commission is collecting stakeholder feedback on the MDR/IVDR amendment proposal through an extended consultation window that began in January 2026, with first‑reading legislation not expected before late H1 2026.​ Innovation, safety and procurement agenda On 16 March 2026, the Commission will host a high‑level conference in Brussels on “Medical Devices: Innovation and Patient Safety,” with sessions on predictability of conformity assessments, the role of expert panels in EU‑level clinical evidence, and operationalising guidance for breakthrough technologies. New EU‑level rules and guidance on procurement are setting the stage for an overhaul in how hospitals buy MedTech and diagnostics, with a stronger emphasis on value‑based purchasing, lifecycle cost, and innovation, which will affect pricing power and tender strategies.​ The Commission continues to publish updated lists of harmonised standards for medical devices, with a January 2026 tranche adding further standards under MDR, which becomes a practical compliance lever for manufacturers re‑baselining technical documentation.​ Market pressure and operating environment EU data highlighted in recent analysis show sustained pressure on MedTech innovation portfolios, with evidence of reduced pipelines, cancelled launches and some production exits from the EU market, driven largely by the cost and complexity of MDR/IVDR compliance.​ Regulatory roadmaps for 2026 emphasise MDR/IVDR milestones such as certificate renewals, PMCF expectations, closer PRRC oversight and notified‑body interpretation trends, all of which are shaping manufacturer resource allocation and go‑no‑go decisions. Commentators warn that 2026–2027 could be a “perfect storm” as legacy devices rush to transition from MDD/AIMDD/IVDD to MDR/IVDR against finite notified‑body capacity, creating real risk of certification gaps and forced device withdrawals for late movers. MedTech M&amp;A and strategic reshaping Bain’s 2026 MedTech M&amp;A report notes that medtech deal value has rebounded above pre‑2023 levels, with a clear boom in portfolio reshaping as large strategics prune non‑core assets and double down on higher‑growth technology platforms.​ Broader European HealthTech/MedTech forecasts for 2026 point to “bigger cheques, fewer bets,” with deal activity concentrating in assets that combine scale, robust clinical validation and AI or data‑driven capabilities rather than pure revenue add‑ons. Analysts expect consolidation to be driven partly by regulatory complexity, with hardware incumbents and large‑cap tech players acquiring software and data innovators to secure “compliance moats” and data sovereignty under the evolving EU regulatory stack. International expansion and AI‑driven MedTech At CES 2026, European AI‑driven MedTech companies showcased solutions geared towards US reimbursement alignment, institutional contracting and governance, signalling a continued push to scale outside Europe despite regulatory headwinds at home.​ The EU’s wider “Digital Omnibus” and AI‑related proposals, though still under negotiation, are designed to synchronise AI Act high‑risk obligations with MDR/IVDR and streamline overlapping cybersecurity and reporting rules, which will directly affect AI‑enabled devices.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

This Week in European MedTech and HealthTech: 13th March ...

Nelson Advisors invited to UCL GBSH Health Executives in ...

Dismantling the Market: The End of Standalone Patient Por...

Analysis of the HealthTech and MedTech Ecosystem on the F...

What are the biggest issues in European HealthTech and Me...

This Week in European MedTech and HealthTech: 6th March ...